Acrivon Therapeutics : Submission of Matters to a Vote of Security Holders Form 8 K

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 20, 2024, Acrivon Therapeutics, Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, a quorum of 27,422,027 shares of the Company's common stock, or 88.81% of the outstanding shares of common stock entitled to vote as of the record date of April 22, 2024, were present or represented by proxy.

Two items of business were acted upon by the stockholders at the Annual Meeting. The final results for the votes regarding each proposal are set forth below.

Proposal One: Election of Kristina Masson, Ph.D., M.B.A; Sharon Shacham, Ph.D., M.B.A.; and Ivana Magovčević-Liebisch, Ph.D., J.D. as Class II Directors.

Kristina Masson, Ph.D., M.B.A; Sharon Shacham, Ph.D., M.B.A.; and Ivana Magovčević-Liebisch, Ph.D., J.D were each elected to serve as a Class II director to hold office until the Company's 2027 Annual Meeting of Stockholders and until the election and qualification of his successor. Votes were cast as follows:

	For	Withheld	Broker Non-Votes
Kristina Masson, Ph.D., M.B.A.		24,563,469		109,386		2,749,172
Sharon Shacham, Ph.D., M.B.A.		23,268,783		1,466,015		2,687,229
Ivana Magovčević-Liebisch, Ph.D., J.D.		24,498,933		237,318		2,685,776

Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm.
The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 by the following vote:

For	Against	Abstain	Broker Non-Votes
27,405,683	6,036	10,308	-